GlassScriptPhysician profile
Joy A Demarcaida
NPI 1841296951
$217,497.46
in general payments reported to CMS, 2019-2025
21 companies · $3,877 in 2025
The $3,877 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $33K · 2021: $53K · 2022: $2,626 · 2023: $8,609 · 2024: $2,478 · 2025: $3,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,150 · Travel and Lodging: $3,871 · Food and Beverage: $2,634 · Consulting Fee: $1,300 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,150.00 |
| Travel and Lodging | $3,871.07 |
| Food and Beverage | $2,633.92 |
| Consulting Fee | $1,300.00 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $55,265.49 | 2019-2023 | Inbrija |
| Acadia Pharmaceuticals INC | $51,802.49 | 2019-2025 | Nuplazid |
| Allergan, INC. | $25,381.02 | 2019-2021 | |
| Abbvie INC. | $21,337.84 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $19,900.86 | 2019-2021 | |
| Kyowa Kirin, INC. | $17,090.03 | 2019-2024 | Nourianz |
| Mdd US Operations, LLC | $15,694.20 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Boston Scientific Corporation | $2,723.57 | 2019-2023 | |
| Insightec,INC | $1,901.23 | 2019-2025 | Exablate |
| Sage Therapeutics, LLC | $1,865.90 | 2022 | |
| Avion Pharmaceuticals | $1,831.21 | 2021-2023 | Dhivy |
| Medtronic, INC. | $1,493.22 | 2021-2025 | Activa PC, Percept PC Brainsense |
| Medtronic USA, INC. | $474.19 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $228.81 | 2019-2023 | Ingrezza |
| Abbott Laboratories | $182.34 | 2025 | Infinity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $94.31 | 2023-2025 | Rytary, Crexont |
| Noctrix Health, INC. | $81.81 | 2024 | Nidra |
| Supernus Pharmaceuticals, INC. | $70.41 | 2025 | Qelbree |
| Ge Healthcare | $44.25 | 2019-2024 | |
| Amgen INC. | $19.74 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Demarcaida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.